Moreira, M A <br/><br/>
Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis.  [electronic resource] 

 -  Acta neurologica Scandinavica  Aug 2006 
 - 109-13 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0001-6314 
<br/><br/><label>Standard No.: </label>10.1111/j.1600-0404.2006.00629.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-Inflammatory Agents--pharmacology<br/>Biomarkers--blood<br/>Chemokine CCL2--blood<br/>Chemokine CXCL10<br/>Chemokines, CXC--blood<br/>Chemotaxis, Leukocyte--immunology<br/>Controlled Clinical Trials as Topic<br/>Down-Regulation--drug effects<br/>Female<br/>Humans<br/>Male<br/>Methylprednisolone--pharmacology<br/>Middle Aged<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Predictive Value of Tests<br/>Treatment Outcome